2.11 Questions of the Week, When RCTs are Necessary, & AYA Oncology with Dr. Adam Duvall

Plenary Session

English - September 12, 2019 16:44 - 1 hour - 100 MB - ★★★★★ - 732 ratings
Science Health & Fitness Medicine medicine oncology health policy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: 2.10 Questions of the Week: the USMLE Step 2 CK, the MKSAP, & Hematology/Oncology

Next Episode: 2.12 Questions of the Week, Ethics of RCTs, & Transmission and Medical Overuse with Dr. Dan Morgan

After a hiatus from our segment on reviewing recent trials, we return to discuss the need for randomized controlled trials (RCTs). In the wake of the 2019 World Conference on Lung Cancer, we focus on whether a phase III trial of selpercatinib (LOXO-292) in RET rearranged lung cancer is feasible, practical, and ethical. We also have two questions of the week in this episode -- one from Dr. Derrick Tao, inspired by the MKSAP; and one from Dr. Sven Olson on hematology and oncology -- as well as an interview with Dr. Adam Duvall of OHSU on his career in the field of adolescent and young adult (AYA) oncology.

Back us on Patreon! patreon.com/plenarysession